Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585446 | 1.00 | MEN1 (0.57) | MEN1KMT2AKDM4ELMNAMAPK1 | |
| SCHEMBL4583951 | 0.89 | KMT2A (0.54) | MEN1KMT2AKDM4EAOC3 | |
| SCHEMBL4583955 | 0.89 | KMT2A (0.54) | MEN1KMT2AKDM4EAOC3 | |
| SCHEMBL4585166 | 0.86 | MEN1 (0.50) | MEN1KMT2AKDM4ECYP1A2CYP2C19 | |
| SCHEMBL4585162 | 0.86 | MEN1 (0.50) | MEN1KMT2AKDM4ECYP1A2CYP2C19 | |
| SCHEMBL5703818 | 0.85 | MEN1 (0.51) | MEN1KMT2AKDM4ELMNAMAPK1 | |
| SCHEMBL4584463 | 0.84 | KCNH2 (0.49) | MEN1KMT2ALMNA | |
| SCHEMBL4584459 | 0.84 | KCNH2 (0.49) | MEN1KMT2ALMNA | |
| SCHEMBL1622181 | 0.75 | MEN1 (0.50) | MEN1KMT2AKDM4E | |
| SCHEMBL18261027 | 0.74 | POLB (0.44) | MEN1KMT2AKDM4EAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417060-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20050137236-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137236-A1 | Aminoalcohol derivatives | GPR39, PRMT9, CHRM2 | MEN1 4146/4885KMT2A 630/4885KDM4E 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.